Secondary analysis shows improvements in lung function metrics over 12 months in asthma patients, suggesting dupilumab influences small airways.
The data that support the findings of this study are available from the corresponding author upon reasonable request. Table S1: Improvement of whole-breath oscillometric variables from baseline (pre-dupilumab) to 3–6 or 12 months of follow-up, according to different studies performed in asthma. Table S2: Baseline characteristics (secondary analysis, N = 51). Figure S1: Lung Function assessed by spirometry (secondary analysis, N = 51). Figure S2: Biomarkers and clinical outcomes (secondary analysis, N = 51). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Martini et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: